All In Biotech

NDA 215110 · Abbvie

Mavyret

Glecaprevir, Pibrentasvir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus NS3/4A Protease Inhibitor

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 10, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

58

30 Phase 3, 3 recruiting

FAERS reports

10,976

2,823 serious, 296 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions ( 5.1 )] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...

What it is approved for

From the label in effect Jun 25, 2025.

MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14 )]. MAVYRET is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. ( 1 )

Mechanism: Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology ( 12.4 ) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 10, 2025 Supplement 5 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jun 10, 2021 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
  • MAVYRET · GLECAPREVIR 50MG/PACKET; PIBRENTASVIR 20MG/PACKET · PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glecaprevir" as an intervention, any sponsor and status, largest first.

All 58 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,568
  • headache2,208
  • nausea1,135
  • pruritus662
  • diarrhoea481
  • vomiting317
  • rash314
  • dizziness232
  • death231
  • pain211
  • insomnia201
  • abdominal discomfort199

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2017156
20183,515
20193,713
20201,203
2021526
2022715
2023437
2024282
2025266
2026163

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mavyret (Glecaprevir/Pibrentasvir)

2024 spending

$165M

Beneficiaries

6,721

12,457 claims

Per beneficiary

$24,598

$155.84 per unit

View as table
YearSpending
2020$295,848,484
2021$259,730,649
2022$235,116,398
2023$232,993,526
2024$165,321,586

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 81 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.